Fortress Biotech, Inc.
Close on Oct 19, 2026
- Market cap
- $59.45M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 13, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | After market close | $18.70M | $-0.08 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | After market close | $16.00M | $2.82 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 31, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 14, 2025 | Before market open | $17.60M | $0.11 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | After market close | $16.40M | $0.45 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | After market close | $13.10M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 31, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | After market close | $14.60M | $-0.76 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 15, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 28, 2024 | After market close | – | – | – |
Press releases
Announcements Fortress Biotech filed with the SEC
Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Results of operations · EX-99 to Form 8-K
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights
Results of operations · EX-99 to Form 8-K
Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
Material agreement · New financial obligation · Other events · EX-99 to Form 8-K
Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission
Other events · EX-99 to Form 8-K
Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
Results of operations · EX-99 to Form 8-K
Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101
Other events · EX-99 to Form 8-K
Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
Results of operations · EX-99 to Form 8-K
Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
Results of operations · EX-99 to Form 8-K
Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
Results of operations · EX-99 to Form 8-K
Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
Other events · EX-99.1 to Form 8-K
Fortress Biotech Reports First Quarter 2024
Results of operations · EX-99.1 to Form 8-K
Fortress Biotech Reports 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Fortress Biotech Announces Pricing of $11 Million
Material agreement · Other events · EX-99.1 to Form 8-K
Fortress Biotech Announces Closing of $11 Million
Material agreement · Other events · EX-99.2 to Form 8-K
Fortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Fortress Biotech Announces Launch of Proposed
Material agreement · Other events · EX-99.1 to Form 8-K
Fortress Biotech Announces Pricing of $10.0
Material agreement · Other events · EX-99.2 to Form 8-K
Fortress Biotech Announces Closing of $10.0
Material agreement · Other events · EX-99.3 to Form 8-K
Fortress Biotech Announces Reverse Stock Split
Charter or bylaw amendment · Shareholder vote results · Other events · EX-99.1 to Form 8-K
Fortress Biotech Reports Second Quarter 2023
Results of operations · Charter or bylaw amendment · EX-99.1 to Form 8-K
Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Fortress Biotech Announces Pricing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Material agreement · Other events · EX-99.1 to Form 8-K
Fortress Biotech Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Fortress Biotech Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Fortress Biotech Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Fortress Biotech Reports Record 2021 Financial
Results of operations · EX-99.1 to Form 8-K